{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:31:28Z","timestamp":1793017888502,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,4,18]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Ponatinib exhibits activity against AC220-resistant FLT3-ITD\/F691 gatekeeper mutations. Ponatinib is highly ineffective against FLT3-ITD activation loop mutations, particularly at the D835 residue.<\/jats:p>","DOI":"10.1182\/blood-2012-07-442871","type":"journal-article","created":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T00:09:00Z","timestamp":1361491740000},"page":"3165-3171","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":117,"title":["Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD"],"prefix":"10.1182","volume":"121","author":[{"given":"Catherine C.","family":"Smith","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, University of California, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.","family":"Lasater","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of California, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhu","sequence":"additional","affiliation":[{"name":"ARIAD Pharmaceuticals, Cambridge, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly C.","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of California, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney K.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of California, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Damon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of California, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Salerno","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of California, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of California, San Francisco, CA;"},{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111818074232500_B1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2141.2000.02317.x","article-title":"FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.","volume":"111","author":"Abu-Duhier","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111818074232500_B2","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111818074232500_B3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111818074232500_B4","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111818074232500_B5","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"issue":"21","key":"2019111818074232500_B6","article-title":"Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients >= 60 years of age with FLT3 ITD positive or negative relapsed\/refractory acute myeloid leukemia.","volume":"120","author":"Cortes","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"2019111818074232500_B7","article-title":"Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed\/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation.","volume":"120","author":"Levis","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"26","key":"2019111818074232500_B8","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","article-title":"Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.","volume":"113","author":"Metzelder","year":"2009","journal-title":"Blood"},{"issue":"7397","key":"2019111818074232500_B9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"issue":"22","key":"2019111818074232500_B10","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","article-title":"Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D835 mutation.","volume":"119","author":"Man","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111818074232500_B11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2005-06-2469","article-title":"Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.","volume":"107","author":"Heidel","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111818074232500_B12","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/0008-5472.CAN-08-2923","article-title":"FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.","volume":"69","author":"von Bubnoff","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"2019111818074232500_B13","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"2","key":"2019111818074232500_B14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"10","key":"2019111818074232500_B15","first-page":"768","article-title":"Systemic mastocytosis: current classification and novel therapeutic options.","volume":"4","author":"Barbie","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"issue":"18 Pt 1","key":"2019111818074232500_B16","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1158\/1078-0432.CCR-06-0858","article-title":"Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.","volume":"13","author":"Desai","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111818074232500_B17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111818074232500_B18","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","article-title":"Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.","volume":"10","author":"Gozgit","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"2019111818074232500_B19","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias.","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"2019111818074232500_B20","article-title":"Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.","volume":"29","author":"Talpaz","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"issue":"10","key":"2019111818074232500_B21","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111818074232500_B22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2141.2012.09085.x","article-title":"Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.","volume":"157","author":"Zirm","year":"2012","journal-title":"Br J Haematol"},{"issue":"30","key":"2019111818074232500_B23","doi-asserted-by":"crossref","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.","volume":"279","author":"Mol","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111818074232500_B24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","article-title":"The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.","volume":"13","author":"Griffith","year":"2004","journal-title":"Mol Cell"},{"issue":"10","key":"2019111818074232500_B25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine.","volume":"15","author":"Azam","year":"2008","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"2019111818074232500_B26","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"issue":"12","key":"2019111818074232500_B27","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"2019111818074232500_B28","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","article-title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.","volume":"23","author":"Corless","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111818074232500_B29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2004-02-0660","article-title":"Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).","volume":"105","author":"Kindler","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111818074232500_B30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2004.05324.x","article-title":"Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3.","volume":"128","author":"Smith","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111818074232500_B31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2006-05-024018","article-title":"Activation mechanisms of STAT5 by oncogenic Flt3-ITD.","volume":"110","author":"Choudhary","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111818074232500_B32","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/1078-0432.CCR-11-2346","article-title":"Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.","volume":"18","author":"Perl","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111818074232500_B33","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.","volume":"71","author":"Eide","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"2019111818074232500_B34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2012.191","article-title":"Mutations of FLT3\/ITD confer resistance to multiple tyrosine kinase inhibitors.","volume":"27","author":"Williams","year":"2013","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/16\/3165\/1330211\/3165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/16\/3165\/1330211\/3165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:07:57Z","timestamp":1574100477000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/16\/3165\/31619\/Activity-of-ponatinib-against-clinicallyrelevant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":34,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,4,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-07-442871","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,18]]}}}